Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KDM6B | O15054 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.30 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393611 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL5000083 | 0.91 | — | — | |
| Ammonia Solution, Strong SCHEMBL11807700 | 0.91 | — | — | |
| SCHEMBL11809093 | 0.91 | — | — | |
| Ethane SCHEMBL5444803 | 0.88 | TSHR (0.50) | TSHRLDHASRREGLN1KDM4E | |
| SCHEMBL5772267 | 0.84 | — | — | |
| SCHEMBL320091 | 0.84 | LDHA (0.61) | TSHRLDHASRREGLN1KDM4E | |
| SCHEMBL320485 | 0.84 | LDHA (0.61) | TSHRLDHASRREGLN1KDM4E | |
| SCHEMBL28522 | 0.80 | LDHA (0.67) | TSHRLDHASRREGLN1KDM4E | |
| SCHEMBL2184678 | 0.80 | LDHA (0.67) | TSHRLDHASRREGLN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109295019-B | Alcohol dehydrogenase mutant and application thereof | 浙江大学 | 2021-01-12 | — | — | CN | claimed |
| WO-2014203045-A1 | A NOVEL, GREEN AND COST EFFECTIVE PROCESS FOR SYNTHESIS OF TERT-BUTYL (3R,5S)-6-OXO-3,5-DIHYDROXY-3,5-O-ISOPROPYLIDENE-HEXANOATE | LUPIN LIMITED (IN) | 2014-12-24 | — | — | WO | disclosed |
| EP-2694490-A1 | PREPARATION OF 3,5-DIOXO HEXANOATE ESTER IN TWO STEPS | Lonza Ltd (CH) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012130919-A1 | PREPARATION OF 3,5-DIOXO HEXANOATE ESTER IN TWO STEPS | LONZA LTD (CH) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012130920-A1 | PREPARATION OF 3,5-DIOXO HEXANOATE ESTER | LONZA LTD (CH) | 2012-10-04 | — | — | WO | disclosed |
| US-20100081839-A1 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA LABORATORIES LTD. (IN) | 2010-04-01 | — | — | US | disclosed |
| EP-2114957-A2 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA Laboratories Limited (IN) | 2009-11-11 | — | — | EP | disclosed |
| US-20080188663-A1 | Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I | IPCA LABORATORIES LIMITED (IN) | 2008-08-07 | — | — | US | disclosed |
| WO-2008093357-A2 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA LABORATORIES LIMITED (IN) | 2008-08-07 | — | — | WO | disclosed |
| WO-2003072793-A2 | METHOD FOR PRODUCING ALCOHOLS FROM SUBSTRATES BY USING OXIDE REDUCTASES, TWO-PHASE SYSTEM COMPRISING AN AQUEOUS PHASE AND AN ORGANIC PHASE AND DEVICE FOR CARRYING OUT SAID METHOD | Forschungszentrum Jülich GmbH (DE) | 2003-09-04 | — | — | WO | disclosed |
| EP-1141373-A1 | METHOD FOR THE ENANTIOSELECTIVE REDUCTION OF 3,5-DIOXOCARBOXYLIC ACIDS, THEIR SALTS AND THEIR ESTERS | FORSCHUNGSZENTRUM JÜLICH GMBH (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000036134-A1 | METHOD FOR THE ENANTIOSELECTIVE REDUCTION OF 3,5-DIOXOCARBOXYLIC ACIDS, THEIR SALTS AND THEIR ESTERS | Forschungszentrum Jülich GmbH (DE) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081839-A1 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | VKORC1, VKORC1L1, PTGER1 | TSHR 3025/4885LDHA 4518/4885SRR 10/4885 |
| US-20080188663-A1 | Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I | CYP2S1, CYP2F1, VKORC1L1 | TSHR 4697/4885LDHA 3958/4885SRR 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.